Our fermentation technologies are focused on developing new production processes that optimize product yields. We have extensive experience in growing a variety of bacterial cultures for the production of vaccine antigens.
Additionally, we have a successful track record of developing media formulations to support the growth of important fish pathogens that have been otherwise deemed non-culturable or difficult to grow.
Our level II biosecure research facility is suited to provide process development services for bacterial and recombinant fermentations at 10 L, 20 L and 100 L volumes.
We are equipped for downstream processing of the fermentation products and are able to formulate batches of experimental vaccines up to 200 L.
